Drug Profile
Travoprost/verosudil
Alternative Names: AR-12286/travoprost; PG-286; Travoprost/AR-12286; Verosudil/travoprostLatest Information Update: 16 Feb 2023
Price :
$50
*
At a glance
- Originator Aerie Pharmaceuticals
- Developer Alcon
- Class Acetamides; Antiglaucomas; Antihypertensives; Isoquinolines; Prostaglandins; Small molecules; Thiophenes
- Mechanism of Action Prostaglandin F2 alpha agonists; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 30 Jun 2013 Discontinued - Phase-II for Glaucoma in USA (Ophthalmic)
- 30 Jun 2013 Discontinued - Phase-II for Ocular hypertension in USA (Ophthalmic)
- 27 Feb 2013 Aerie Pharmaceuticals initiates enrolment in a phase IIb trial for Glaucoma or Ocular hypertension in USA (NCT01789736)